{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:44:39Z","timestamp":1782200679373,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-025-02633-w","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T07:22:26Z","timestamp":1765351346000},"page":"497-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-3452","authenticated-orcid":false,"given":"Utku","family":"Soyaltin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilgin Y.","family":"Simsir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"11","key":"2633_CR1","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"Garg A (2011) Clinical review#: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 96(11):3313\u201325. https:\/\/doi.org\/10.1210\/jc.2011-1159","journal-title":"J Clin Endocrinol Metab."},{"key":"2633_CR2","unstructured":"Akinci B, Gular MC, Oral EA. Lipodystrophy Syndromes: Presentation and Treatment. 2024 Aug 21. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferr\u00e8re B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors (2000) Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc"},{"key":"2633_CR3","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/myalepta."},{"issue":"5","key":"2633_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2337\/dc24-2408","volume":"48","author":"R Meral","year":"2025","unstructured":"Meral R, Celik Guler M, Kaba D, Prativadi J, Frontera ED, Foss-Freitas MC, Nachawi N, Broome DT, Lightbourne M, Brown RJ, Taylor SI, Oral EA (2025) Metabolic improvements with tirzepatide in lipodystrophy: a novel option? Diabetes Care 48(5):756\u2013762. https:\/\/doi.org\/10.2337\/dc24-2408","journal-title":"Diabetes Care"},{"issue":"4","key":"2633_CR5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2337\/dc23-1614","volume":"47","author":"MC Foss-Freitas","year":"2024","unstructured":"Foss-Freitas MC, Imam S, Neidert A, Gomes AD, Broome DT, Oral EA (2024) Efficacy and safety of glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy. Diabetes Care 47(4):653\u2013659. https:\/\/doi.org\/10.2337\/dc23-1614","journal-title":"Diabetes Care"},{"issue":"4","key":"2633_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","volume":"133","author":"E Arioglu","year":"2000","unstructured":"Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE, Hoofnagle J, Reitman ML, Taylor SI (2000) Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 133(4):263\u2013274. https:\/\/doi.org\/10.7326\/0003-4819-133-4-200008150-00009","journal-title":"Ann Intern Med"},{"issue":"6","key":"2633_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.2337\/db17-1236","volume":"67","author":"M Agostini","year":"2018","unstructured":"Agostini M, Schoenmakers E, Beig J, Fairall L, Szatmari I, Rajanayagam O, Muskett FW, Adams C, Marais AD, O\u2019Rahilly S, Semple RK, Nagy L, Majithia AR, Schwabe JWR, Blom DJ, Murphy R, Chatterjee K, Savage DB (2018) A pharmacogenetic approach to the treatment of patients with PPARG mutations. Diabetes 67(6):1086\u20131092. https:\/\/doi.org\/10.2337\/db17-1236","journal-title":"Diabetes"},{"issue":"6","key":"2633_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2174\/1573399813666170816142351","volume":"14","author":"MG Minze","year":"2018","unstructured":"Minze MG, Will KJ, Terrell TB, Black RL, Irons BK (2018) Benefits of SGLT2 inhibitors beyond glycemic control - a focus on metabolic, cardiovascular and renal outcomes. Curr Diabetes Rev 14(6):509\u2013517. https:\/\/doi.org\/10.2174\/1573399813666170816142351","journal-title":"Curr Diabetes Rev"},{"issue":"2","key":"2633_CR9","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.84353","volume":"17","author":"S Rabizadeh","year":"2019","unstructured":"Rabizadeh S, Nakhjavani M, Esteghamati A (2019) Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review. Int J Endocrinol Metab 17(2):e84353. https:\/\/doi.org\/10.5812\/ijem.84353","journal-title":"Int J Endocrinol Metab"},{"issue":"2","key":"2633_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","volume":"65","author":"LL Lai","year":"2020","unstructured":"Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK (2020) Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci 65(2):623\u2013631. https:\/\/doi.org\/10.1007\/s10620-019-5477-1","journal-title":"Dig Dis Sci"},{"issue":"5","key":"2633_CR11","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/jdi.12825","volume":"9","author":"T Hamaguchi","year":"2018","unstructured":"Hamaguchi T, Hirota Y, Takeuchi T, Nakagawa Y, Matsuoka A, Matsumoto M, Awano H, Iijima K, Cha PC, Satake W, Toda T, Ogawa W (2018) Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter\u00a02 inhibitor. J Diabetes Investig. 9(5):1224\u20131227. https:\/\/doi.org\/10.1111\/jdi.12825","journal-title":"J Diabetes Investig."},{"issue":"6","key":"2633_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.7326\/L16-0372","volume":"166","author":"Y Kawana","year":"2017","unstructured":"Kawana Y, Imai J, Sawada S, Yamada T, Katagiri H (2017) Sodium-glucose cotransporter 2 inhibitor improves complications of lipodystrophy: a case report. Ann Intern Med 166(6):450\u2013451. https:\/\/doi.org\/10.7326\/L16-0372","journal-title":"Ann Intern Med"},{"issue":"6","key":"2633_CR13","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.eprac.2022.03.006","volume":"28","author":"R Bansal","year":"2022","unstructured":"Bansal R, Cochran E, Startzell M, Brown RJ (2022) Clinical effects of sodium-glucose transporter type 2 inhibitors in patients with partial lipodystrophy. Endocr Pract. 28(6):610\u2013614. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.006","journal-title":"Endocr Pract."},{"key":"2633_CR14","doi-asserted-by":"publisher","unstructured":"Kidney disease: improving global outcomes (KDIGO) Diabetes Work Group (2022) KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 102(5S):S1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008","DOI":"10.1016\/j.kint.2022.06.008"},{"issue":"5","key":"2633_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.diabet.2007.04.005","volume":"33","author":"F Moreau","year":"2007","unstructured":"Moreau F, Boullu-Sanchis S, Vigouroux C, Lucescu C, Lascols O, Sapin R, Ruimy D, Guerci B, Pinget M, Jeandidier N (2007) Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab 33(5):385\u2013389. https:\/\/doi.org\/10.1016\/j.diabet.2007.04.005","journal-title":"Diabetes Metab"},{"issue":"2","key":"2633_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.diabet.2009.01.001","volume":"35","author":"C Collet-Gaudillat","year":"2009","unstructured":"Collet-Gaudillat C, Billon-Bancel A, Beressi JP (2009) Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. Diabetes Metab 35(2):151\u2013154. https:\/\/doi.org\/10.1016\/j.diabet.2009.01.001","journal-title":"Diabetes Metab"},{"issue":"11","key":"2633_CR17","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/j.1464-5491.2005.01757.x","volume":"22","author":"A L\u00fcdtke","year":"2005","unstructured":"L\u00fcdtke A, Heck K, Genschel J, Mehnert H, Spuler S, Worman HJ, Schmidt HH (2005) Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone. Diabet Med 22(11):1611\u20131613. https:\/\/doi.org\/10.1111\/j.1464-5491.2005.01757.x","journal-title":"Diabet Med"},{"issue":"3","key":"2633_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1530\/EJE-08-0272","volume":"159","author":"A Gambineri","year":"2008","unstructured":"Gambineri A, Semple RK, Forlani G, Genghini S, Grassi I, Hyden CS, Pagotto U, O\u2019Rahilly S, Pasquali R (2008) Monogenic polycystic ovary syndrome due to a mutation in the lamin A\/C gene is sensitive to thiazolidinediones but not to metformin. Eur J Endocrinol 159(3):347\u2013353. https:\/\/doi.org\/10.1530\/EJE-08-0272","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2633_CR19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1046\/j.1464-5491.2003.01034.x","volume":"20","author":"KR Owen","year":"2003","unstructured":"Owen KR, Donohoe M, Ellard S, Hattersley AT (2003) Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene. Diabet Med 20(10):823\u2013827. https:\/\/doi.org\/10.1046\/j.1464-5491.2003.01034.x","journal-title":"Diabet Med"},{"issue":"6","key":"2633_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.4158\/EP.13.6.656","volume":"13","author":"GG Sleilati","year":"2007","unstructured":"Sleilati GG, Leff T, Bonnett JW, Hegele RA (2007) Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. Endocr Pract 13(6):656\u2013661. https:\/\/doi.org\/10.4158\/EP.13.6.656","journal-title":"Endocr Pract"},{"issue":"10","key":"2633_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.17863\/CAM.13055","volume":"33","author":"T Demir","year":"2016","unstructured":"Demir T, Onay H, Savage DB et al (2016) Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -gamma (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A\/C (LMNA) mutations. Diabet Med 33(10):1445\u20131450. https:\/\/doi.org\/10.17863\/CAM.13055","journal-title":"Diabet Med"},{"issue":"22","key":"2633_CR22","doi-asserted-by":"publisher","first-page":"12060","DOI":"10.3390\/ijms252212060","volume":"25","author":"A Hummadi","year":"2024","unstructured":"Hummadi A, Yafei S, Mutawwam DA, Abutaleb R, Solan Y, Khawaji A, Alhagawy AJ, Algohani T, Khardali M, Hakami M, Daghriri A, Hezam W, Kariri N (2024) Genomic and bioinformatics analysis of familial partial lipodystrophy Type 3 identified in a patient with novel PPAR\u03b3 mutation and robust response to pioglitazone. Int J Mol Sci 25(22):12060. https:\/\/doi.org\/10.3390\/ijms252212060","journal-title":"Int J Mol Sci"},{"issue":"13","key":"2633_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.830708","volume":"29","author":"X Chen","year":"2022","unstructured":"Chen X, Ma Z, Chen P, Song X, Li W, Yu X, Xie J (2022) Case report: a new peroxisome proliferator-activated receptor gamma mutation causes familial partial lipodystrophy Type 3 in a Chinese patient. Front Endocrinol (Lausanne) 29(13):830708. https:\/\/doi.org\/10.3389\/fendo.2022.830708","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2633_CR24","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2337\/diabetes.52.4.910","volume":"52","author":"DB Savage","year":"2003","unstructured":"Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O\u2019Rahilly S (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52(4):910\u2013917. https:\/\/doi.org\/10.2337\/diabetes.52.4.910","journal-title":"Diabetes"},{"issue":"8","key":"2633_CR25","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2337\/dc18-0588","volume":"41","author":"MJB van Baar","year":"2018","unstructured":"van Baar MJB, van Ruiten CC, Muskiet MHA, van Bloemendaal L, IJzerman RG, van Raalte DH (2018) SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 41(8):1543\u20131556. https:\/\/doi.org\/10.2337\/dc18-0588","journal-title":"Diabetes Care"},{"issue":"2","key":"2633_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3223","volume":"36","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Geng Z, Wang X, Huang Y, Shen L, Wang Y (2020) Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes. Diabetes Metab Res Rev. 36(2):e3223. https:\/\/doi.org\/10.1002\/dmrr.3223","journal-title":"Diabetes Metab Res Rev."},{"key":"2633_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106667","volume":"188","author":"E Osto","year":"2023","unstructured":"Osto E, Bonacina F, Pirillo A, Norata GD (2023) Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms. Pharmacol Res 188:106667. https:\/\/doi.org\/10.1016\/j.phrs.2023.106667","journal-title":"Pharmacol Res"},{"issue":"7","key":"2633_CR28","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/oby.22864","volume":"28","author":"S Carbone","year":"2020","unstructured":"Carbone S, O\u2019Keefe JH, Lavie CJ (2020) SGLT2 inhibition, visceral adiposity, weight, and Type 2 Diabetes mellitus. Obesity (Silver Spring) 28(7):1173. https:\/\/doi.org\/10.1002\/oby.22864","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"2633_CR29","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc21-2043","volume":"45","author":"RA Herring","year":"2022","unstructured":"Herring RA, Shojaee-Moradie F, Stevenage M, Parsons I, Jackson N, Mendis J, Middleton B, Umpleby AM, Fielding BA, Davies M, Russell-Jones DL (2022) The SGLT2 inhibitor dapagliflozin increases the oxidation of ingested fatty acids to ketones in type 2 diabetes. Diabetes Care 45(6):1408\u20131415. https:\/\/doi.org\/10.2337\/dc21-2043","journal-title":"Diabetes Care"},{"issue":"1","key":"2633_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","volume":"22","author":"CJ Bailey","year":"2022","unstructured":"Bailey CJ, Day C, Bellary S (2022) Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 22(1):39\u201352. https:\/\/doi.org\/10.1007\/s11892-021-01442-z","journal-title":"Curr Diab Rep."},{"issue":"1","key":"2633_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/cen.13732","volume":"89","author":"B Akinci","year":"2018","unstructured":"Akinci B, Unlu SM, Celik A, Simsir IY, Sen S, Nur B, Keskin FE, Ozgen Saydam B, Kutbay Ozdemir N, Sarer Yurekli B, Ergur BU, Sonmez M, Atik T, Arslan A, Demir T, Altay C, Tunc UA, Arkan T, Gen R, Eren E, Akinci G, Yilmaz AA, Bilen H, Ozen S, Celtik A, Savas Erdeve S, Cetinkaya S, Onay H, Sarioglu S, Oral EA (2018) Renal complications of lipodystrophy: a closer look at the natural history of kidney disease. Clin Endocrinol (Oxf). 89(1):65\u201375. https:\/\/doi.org\/10.1111\/cen.13732","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"2633_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000533992","volume":"17","author":"MC Foss-Freitas","year":"2024","unstructured":"Foss-Freitas MC, Besci \u00d6, Meral R, Neidert A, Chenevert TL, Oral EA, Rothberg AE (2024) A very-low-calorie diet can cause remission of diabetes mellitus and hypertriglyceridemia in familial partial lipodystrophy. Obes Facts. 17(1):103\u2013108. https:\/\/doi.org\/10.1159\/000533992","journal-title":"Obes Facts."},{"issue":"10","key":"2633_CR33","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1210\/jc.2017-01235","volume":"102","author":"A Melvin","year":"2017","unstructured":"Melvin A, Adams C, Flanagan C, Gaff L, Gratton B, Gribble F, Roberts G, Semple RK, O\u2019Rahilly S, Rubino F, Stears A, Savage DB (2017) Roux-en-Y gastric bypass surgery in the management of familial partial lipodystrophy type 1. J Clin Endocrinol Metab 102(10):3616\u20133620. https:\/\/doi.org\/10.1210\/jc.2017-01235","journal-title":"J Clin Endocrinol Metab"},{"issue":"9309","key":"2633_CR34","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M Zander","year":"2002","unstructured":"Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359(9309):824\u2013830. https:\/\/doi.org\/10.1016\/S0140-6736(02)07952-7","journal-title":"Lancet"},{"issue":"9","key":"2633_CR35","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s00125-013-2957-2","volume":"56","author":"JH Ellenbroek","year":"2013","unstructured":"Ellenbroek JH, T\u00f6ns HA, van Westerouen Meeteren MJ, de Graaf N, Hanegraaf MA, Rabelink TJ, Carlotti F, de Koning EJ (2013) Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia 56(9):1980\u20131986. https:\/\/doi.org\/10.1007\/s00125-013-2957-2","journal-title":"Diabetologia"},{"issue":"11","key":"2633_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049152","volume":"7","author":"ET Parlevliet","year":"2012","unstructured":"Parlevliet ET, Wang Y, Geerling JJ, der Schr\u00f6-Van Elst JP, Picha K, O\u2019Neil K, Stojanovic-Susulic V, Ort T, Havekes LM, Romijn JA, Pijl H, Rensen PC (2012) GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS ONE 7(11):e49152. https:\/\/doi.org\/10.1371\/journal.pone.0049152","journal-title":"PLoS ONE"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02633-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-025-02633-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02633-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:03:57Z","timestamp":1775131437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-025-02633-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["2633"],"URL":"https:\/\/doi.org\/10.1007\/s00592-025-02633-w","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BA attended advisory board meetings organized by Amryt Pharmaceuticals and Regeneron Pharmaceuticals and has served as a consultant and\/or received honoraria as a speaker from Third Rock Ventures, Amryt, Regeneron, AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis. Other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board (IRB) of the Dokuz Eylul University Medical School Hospital (IRB; 7364 GOA) in accordance with the Declaration of Helsinki. The study involves prospectively collected data so informed consent was taken all of the study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}